We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.99%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$725M
AUM Growth
+$66.7M
Cap. Flow
+$16.4M
Cap. Flow %
2.26%
Top 10 Hldgs %
41.88%
Holding
145
New
38
Increased
32
Reduced
27
Closed
36

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$25.1M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$19.4M
3
AMGN icon
Amgen
AMGN
+$17.7M
4
BLUE
bluebird bio
BLUE
+$12.8M
5
VTRS icon
Viatris
VTRS
+$11M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$28.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.3M
3
SHPG
Shire pic
SHPG
+$11.3M
4
FOLD
Amicus Therapeutics
FOLD
+$9.93M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.8M

Sector Composition

Rank Sector Weight
1 Healthcare 72.21%
2 Technology 6.12%
3 Financials 1.97%
4 Industrials 1.58%
5 Consumer Discretionary 1.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CHTR icon
101
Charter Communications
CHTR
$17.3B
$416K 0.06%
1,419
-1,910
-57% -$549K
SITE icon
102
SiteOne Landscape Supply
SITE
$4.12B
$252K 0.03%
3,000
– –
MHK icon
103
Mohawk Industries
MHK
$7.5B
$236K 0.03%
1,100
– –
CISN
104
DELISTED
Cision Ltd. Ordinary Share
CISN
$224K 0.03%
+15,000
New +$211K
SNA icon
105
Snap-on
SNA
$21.2B
$220K 0.03%
1,366
– –
EIDX
106
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$220K 0.03%
+10,828
New +$227K
ULTI
107
DELISTED
Ultimate Software Group Inc
ULTI
$206K 0.03%
800
– –
ZVRA icon
108
Zevra Therapeutics
ZVRA
$562M
$147K 0.02%
+1,414
New +$138K
CHRS icon
109
Coherus Oncology
CHRS
$217M
– –
-270,000
Closed -$2.98M
CMCSA icon
110
Comcast
CMCSA
$85B
– –
-10,000
Closed -$342K
EXPE icon
111
Expedia Group
EXPE
$35.4B
– –
-18,900
Closed -$2.09M
KYNB
112
Kyntra Bio
KYNB
$27.2M
– –
-1,591
Closed -$1.84M
LPSN icon
113
LivePerson
LPSN
$21.8M
– –
-9
Closed -$2K
MGNX icon
114
MacroGenics
MGNX
$235M
– –
-135,000
Closed -$3.4M
MNOV icon
115
MediciNova
MNOV
$65.5M
– –
-630,838
Closed -$6.45M
NTLA icon
116
Intellia Therapeutics
NTLA
$1.49B
– –
-160,000
Closed -$3.37M
PBYI icon
117
Puma Biotechnology
PBYI
$404M
– –
-60,000
Closed -$4.08M
PRGO icon
118
Perrigo
PRGO
$1.4B
– –
-19,221
Closed -$1.6M
QQQ icon
119
PUT
Invesco QQQ Trust
QQQ
$453B
– –
-80,000
Closed -$12.8M
REGN icon
120
Regeneron Pharmaceuticals
REGN
$78.5B
– –
-41,500
Closed -$14.3M
RGNX icon
121
Regenxbio
RGNX
$620M
– –
-100,000
Closed -$2.98M
SEE
122
DELISTED
Sealed Air
SEE
– –
-4,500
Closed -$193K
SNDX icon
123
Syndax Pharmaceuticals
SNDX
$1.69B
– –
-298,472
Closed -$4.25M
VTVT icon
124
vTv Therapeutics
VTVT
$127M
– –
-7,042
Closed -$1.15M
WSO icon
125
Watsco Inc
WSO
$12.7B
– –
-2,100
Closed -$380K
2 3 4
5
6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2018 Portfolio in Review

As of Q2 2018, Sphera Funds Management held 145 positions worth $725M, up 10% from $659M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Sphera Funds Management's Q2 2018 filing shows 38 new, 32 increased, 27 reduced and 36 closed positions. Its largest new stake was Gilead Sciences: 355,000 shares worth $25.1M. The largest sale was Celgene Corp, an estimated $28.5M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 75% a quarter earlier, followed by Technology and Financials.

  • Sphera Funds Management's largest Q2 2018 buy was Gilead Sciences: 355,000 shares worth $25.1M.
  • Sphera Funds Management added most to Viatris in Q2 2018, an estimated $11M increase.
  • Sphera Funds Management's biggest Q2 2018 reduction was Shire pic, cutting an estimated $11.3M.
  • Sphera Funds Management fully exited Celgene Corp in Q2 2018, selling an estimated $28.5M.
  • Sphera Funds Management's ten largest holdings make up 42% of its $725M portfolio in Q2 2018.
  • Sphera Funds Management opened 38 new positions and closed 36 in Q2 2018.
  • Sphera Funds Management's portfolio value rose 10% quarter-over-quarter to $725M.

Based on Sphera Funds Management's 13F filing for Q2 2018, filed 13 Aug 2018.